(R)-2-(羧甲基)吡咯烷盐酸盐 | 101555-60-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (R)-2-(羧甲基)吡咯烷盐酸盐
• 中文别名: Boc-D-Beta-高脯氨酸；(R)-1-Boc-2-吡咯烷乙酸；N-BOC-D-Β-同脯氨酸；N-BOC-D-Beta-高脯氨酸；(R)-吡咯烷-2-乙酸盐酸盐
• 英文名称: (R)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)acetic acid
• 英文别名: 2-[(2R)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-2-yl]acetic acid
• CAS: 101555-60-6
• 化学式: C₁₁H₁₉NO₄
• 分子量: 229.276
• InChiKey: GDWKIRLZWQQMIE-MRVPVSSYSA-N

物化性质

• 沸点：
  357.4±15.0 °C(Predicted)
• 密度：
  1.151±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Boc-D-beta-homoproline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Boc-D-beta-homoproline
CAS number: 101555-60-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H19NO4
Molecular weight: 229.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (R)-2-(羧甲基)吡咯烷盐酸盐 在 lithium aluminium tetrahydride 、 2-碘酰基苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 4.0h， 生成 tert-butyl (2R)-2-(2-oxoethyl)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  新型多目标环胺衍生物多靶嗪磺酰胺可作为潜在的抗精神病药，具有促社会和促认知作用

  摘要：

  当前使用的抗精神病药的特征在于多受体作用方式。尽管多巴胺D 2受体的拮抗作用可减轻精神分裂症的“阳性”症状，而对其他（尤其是血清素能受体）的作用对于它们的附加治疗作用是必需的，但对于“理想的”靶标结合尚无共识。在此，对涉及环芳基-哌嗪/哌啶药效团，中心脂环族胺和嗪磺酰胺基团的45种新颖的环胺衍生物的新型嗪磺酰胺进行了详细的SAR分析，导致选择了（S）-4-（（2-（ 2-（4-（苯并[ b ]噻吩-4-基）哌嗪-1-基）乙基）吡咯烷-1-基磺酰基）异喹啉（62）。62的多药理学特征是部分5-HT 1A R拮抗作用，5-HT 2A / 5-HT 7 / D 2 / D 3 R拮抗作用和对SERT的阻断，降低了“阳性”样和“阴性”似精神病的症状。化合物62不产生僵直症，显示出高催乳激素缺乏症，并在新颖的物体识别任务和注意力转移试验中表现出促认知作用。虽然仍未完全确定体外特征与有希望的体内分布相

  DOI：

  10.1016/j.ejmech.2018.01.002
• 作为产物：
  描述：

  (R)-2-(甲苯磺酰氧基甲基)吡咯烷-1-甲酸叔丁酯 在 sodium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 生成 (R)-2-(羧甲基)吡咯烷盐酸盐
  参考文献：
  名称：

  Conioidine A 的合成和立体化学分配：四种非对映异构体的 DNA 和 HSA 结合研究

  摘要：

  Conioidine A ( 1 ) 于 1993 年以未知的相对和绝对构型分离出来，通过间接技术被认为是一种 DNA 结合化合物。已从d - 和l - 脯氨酸合成了 conioidine A 的四种立体异构体，并且已确定天然产物具有 (4 R ,6 R ) 绝对构型。已经通过荧光光谱法和等温滴定量热法 (ITC) 研究了 conioidine 非对映异构体与小牛胸腺 DNA (CT DNA) 和人血清白蛋白 (HSA) 的结合。所有立体异构体与 DNA 的结合至少比对照化合物 netropsin 弱一个数量级；然而，观察到 (4 R,6 S ) 立体异构体。

  DOI：

  10.1021/acs.jnatprod.0c00871

文献信息

• Sulfonamides having antiangiogenic and anticancer activity
  申请人：——

  公开号：US20040157836A1

  公开（公告）日：2004-08-12

  Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.

  描述了具有蛋氨酸氨基肽酶-2抑制剂（MetAP2）的化合物。还描述了包括这些化合物的药物组合物、使用这些化合物的治疗方法、抑制血管生成的方法以及治疗癌症的方法。
• [EN] N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS<br/>[FR] DÉRIVÉS DE N-HÉTÉROARYLALKYLE-2-(HÉTÉROCYCLYLE ET HÉTÉROCYCLYLMÉTHYLE) ACÉTAMIDE UTILISÉS EN TANT QU'AGONISTES DE SSTR4
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2021202781A1

  公开（公告）日：2021-10-07

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L, n, R1, R2, R6, R7, R8, R9, R10, X3, X4 and X5 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

  揭示了Formula 1的化合物及其药用盐，其中L、n、R1、R2、R6、R7、R8、R9、R10、X3、X4和X5在说明书中有定义。本公开还涉及制备Formula 1化合物的材料和方法，包含它们的药物组合物，以及它们用于治疗与SSTR4相关的疾病、疾患和症状的用途。
• Histamine H3 Inverse Agonists and Antagonists and Methods of Use Thereof
  申请人：Chytil Milan

  公开号：US20110065694A1

  公开（公告）日：2011-03-17

  Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including, e.g., neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as, e.g., histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical compositions containing the compounds and their methods of use are also provided herein.

  本文提供了融合咪唑基化合物，其合成方法以及使用方法。本文提供的化合物可用于治疗、预防和/或管理各种疾病，包括但不限于神经系统疾病和代谢性疾病。本文提供的化合物抑制组胺H3受体的活性，并调节各种神经递质的释放，例如组胺、乙酰胆碱、去甲肾上腺素和多巴胺（例如在突触处）。本文还提供了含有这些化合物的药物组合物及其使用方法。
• Total Synthesis of Tambromycin Enabled by Indole C–H Functionalization
  作者：Galen P. Miley、Jennifer C. Rote、Richard B. Silverman、Neil L. Kelleher、Regan J. Thomson

  DOI：10.1021/acs.orglett.8b00700

  日期：2018.4.20

  The total synthesis of tambromycin (1), a recently isolated tetrapeptide, is reported. This unusual natural product possesses a highly modified tryptophan-derived indole fragment fused to an α-methylserine-derived oxazoline ring, and a unique noncanonical amino acid residue named tambroline (11). A convergent synthesis of tambromycin was achieved by a 13-step route that leveraged recent developments

  据报道，最近分离出的四肽坦布霉素（1）的总合成。这种不寻常的天然产物具有与α-甲基丝氨酸衍生的恶唑啉环融合的高度修饰的色氨酸衍生的吲哚片段，以及一个独特的非规范氨基酸残基，名为tambroline（11）。通过13个步骤的路线，利用C–H功能化领域的最新进展制备了复杂的吲哚片段，并有效合成了具有非对映选择性的高脯氨酸氨溴灵，从而实现了坦布霉素的聚合合成。
• 一种四氢吡啶并[3,4-d]嘧啶衍生物及其在医药上的应用
  申请人：四川海思科制药有限公司

  公开号：CN112442029A

  公开（公告）日：2021-03-05

  本发明涉及一种通式(I)所述的化合物或者其立体异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶，及其中间体和制备方法，以及在制备治疗与KRas‑G12C活性或表达量相关疾病的药物中的应用。